| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
|
J Nucl Med
|
2006
|
7.40
|
|
2
|
Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.
|
Clin Cancer Res
|
2005
|
3.71
|
|
3
|
Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging.
|
Clin Cancer Res
|
2004
|
3.13
|
|
4
|
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
|
Clin Cancer Res
|
2010
|
2.44
|
|
5
|
Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
|
Clin Pharmacol Ther
|
2005
|
2.35
|
|
6
|
A definition of molecular imaging.
|
J Nucl Med
|
2007
|
2.26
|
|
7
|
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
|
J Clin Oncol
|
2006
|
2.12
|
|
8
|
The progress and promise of molecular imaging probes in oncologic drug development.
|
Clin Cancer Res
|
2005
|
1.97
|
|
9
|
Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.
|
J Nucl Med
|
2005
|
1.87
|
|
10
|
Breast cancer, version 3.2013: featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2013
|
1.79
|
|
11
|
FDG PET, PET/CT, and breast cancer imaging.
|
Radiographics
|
2007
|
1.72
|
|
12
|
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
|
J Clin Oncol
|
2008
|
1.60
|
|
13
|
Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
|
J Nucl Med
|
2005
|
1.59
|
|
14
|
Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
|
J Nucl Med
|
2008
|
1.57
|
|
15
|
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
|
Breast Cancer Res Treat
|
2007
|
1.48
|
|
16
|
18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.
|
J Nucl Med
|
2004
|
1.46
|
|
17
|
Locally advanced and inflammatory breast cancer.
|
J Clin Oncol
|
2008
|
1.44
|
|
18
|
Invasive breast cancer.
|
J Natl Compr Canc Netw
|
2011
|
1.43
|
|
19
|
Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
|
J Nucl Med
|
2006
|
1.40
|
|
20
|
Radionuclide breast cancer imaging 2013: state of the art.
|
Semin Nucl Med
|
2013
|
1.39
|
|
21
|
SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
|
J Nucl Med
|
2003
|
1.37
|
|
22
|
Evolving role of positron emission tomography in breast cancer imaging.
|
Semin Nucl Med
|
2005
|
1.33
|
|
23
|
Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy.
|
Acad Radiol
|
2002
|
1.30
|
|
24
|
[11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma.
|
Ann Surg Oncol
|
2006
|
1.29
|
|
25
|
Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.
|
J Nucl Med
|
2009
|
1.27
|
|
26
|
Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
|
J Nucl Med
|
2007
|
1.27
|
|
27
|
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.
|
J Natl Compr Canc Netw
|
2007
|
1.26
|
|
28
|
18F-Fluorothymidine radiation dosimetry in human PET imaging studies.
|
J Nucl Med
|
2003
|
1.23
|
|
29
|
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2012
|
1.23
|
|
30
|
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
|
Clin Nucl Med
|
2011
|
1.23
|
|
31
|
Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.
|
J Nucl Med
|
2009
|
1.21
|
|
32
|
Comparison of different quantitative approaches to 18F-fluoride PET scans.
|
J Nucl Med
|
2004
|
1.19
|
|
33
|
ACR Appropriateness Criteria Breast Cancer Screening.
|
J Am Coll Radiol
|
2013
|
1.18
|
|
34
|
Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
|
J Pharmacol Exp Ther
|
2006
|
1.16
|
|
35
|
Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy.
|
Acad Radiol
|
2004
|
1.14
|
|
36
|
Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.
|
Clin Cancer Res
|
2010
|
1.13
|
|
37
|
PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
|
Clin Cancer Res
|
2011
|
1.12
|
|
38
|
Current and future uses of positron emission tomography in breast cancer imaging.
|
Semin Nucl Med
|
2004
|
1.11
|
|
39
|
Medullary thyroid cancer: options for systemic therapy of metastatic disease?
|
J Clin Oncol
|
2006
|
1.10
|
|
40
|
Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
|
Cancer
|
2005
|
1.09
|
|
41
|
Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC).
|
Am J Clin Oncol
|
2004
|
1.08
|
|
42
|
18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
|
J Nucl Med
|
2004
|
1.07
|
|
43
|
18F-Fluoroestradiol.
|
Semin Nucl Med
|
2007
|
1.06
|
|
44
|
Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases.
|
J Nucl Med
|
2010
|
1.04
|
|
45
|
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
|
J Nucl Med
|
2011
|
1.02
|
|
46
|
Design considerations for using PET as a response measure in single site and multicenter clinical trials.
|
Acad Radiol
|
2011
|
1.02
|
|
47
|
PET/CT imaging in cancer: current applications and future directions.
|
Cancer
|
2014
|
1.02
|
|
48
|
Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer.
|
Nucl Med Biol
|
2011
|
1.01
|
|
49
|
Gastric linitis plastica from metastatic breast carcinoma: FDG and FES PET appearances.
|
AJR Am J Roentgenol
|
2007
|
1.01
|
|
50
|
Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.
|
J Nucl Med
|
2002
|
0.99
|
|
51
|
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
|
Clin Cancer Res
|
2011
|
0.98
|
|
52
|
True tracers: comparing FDG with glucose and FLT with thymidine.
|
Nucl Med Biol
|
2005
|
0.97
|
|
53
|
Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
|
J Magn Reson Imaging
|
2010
|
0.96
|
|
54
|
Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
|
Radiographics
|
2002
|
0.95
|
|
55
|
Positron emission tomography imaging of brain tumors.
|
Neuroimaging Clin N Am
|
2003
|
0.94
|
|
56
|
Quantitative assessment of dynamic PET imaging data in cancer imaging.
|
Magn Reson Imaging
|
2012
|
0.94
|
|
57
|
Quantitative positron emission tomography imaging to measure tumor response to therapy: what is the best method?
|
Mol Imaging Biol
|
2003
|
0.93
|
|
58
|
Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate.
|
J Nucl Med
|
2009
|
0.91
|
|
59
|
Early experiences in establishing a regional quantitative imaging network for PET/CT clinical trials.
|
Magn Reson Imaging
|
2012
|
0.91
|
|
60
|
Internal mammary nodal chain drainage is a prognostic indicator in axillary node-positive breast cancer.
|
Ann Surg Oncol
|
2007
|
0.90
|
|
61
|
Advances in molecular imaging for breast cancer detection and characterization.
|
Breast Cancer Res
|
2012
|
0.89
|
|
62
|
[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.89
|
|
63
|
Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.
|
J Nucl Med
|
2013
|
0.88
|
|
64
|
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
|
Mol Imaging Biol
|
2013
|
0.87
|
|
65
|
Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.
|
Acad Radiol
|
2008
|
0.86
|
|
66
|
The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 1--overview, detection, and staging.
|
J Nucl Med
|
2009
|
0.86
|
|
67
|
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients.
|
EJNMMI Res
|
2012
|
0.86
|
|
68
|
Accuracy of CT-based attenuation correction in PET/CT bone imaging.
|
Phys Med Biol
|
2012
|
0.85
|
|
69
|
The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 2--response to therapy, other indications, and future directions.
|
J Nucl Med
|
2009
|
0.85
|
|
70
|
Adoptive T-cell therapy for the treatment of solid tumours.
|
Expert Opin Biol Ther
|
2002
|
0.85
|
|
71
|
Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: compartmental model investigation and mathematical analysis.
|
Mol Imaging
|
2002
|
0.84
|
|
72
|
A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
|
J Nucl Med
|
2015
|
0.84
|
|
73
|
2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome.
|
Clin Cancer Res
|
2002
|
0.83
|
|
74
|
Beyond detection: novel applications for PET imaging to guide cancer therapy.
|
J Nucl Med
|
2007
|
0.83
|
|
75
|
Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs.
|
Clin Trials
|
2013
|
0.82
|
|
76
|
Breast cancer and hormonal stimulation: is glycolysis the first sign of response?
|
J Nucl Med
|
2010
|
0.82
|
|
77
|
Multiagent PET for risk characterization in sarcoma.
|
J Nucl Med
|
2011
|
0.81
|
|
78
|
Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression.
|
Head Neck
|
2006
|
0.81
|
|
79
|
Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging.
|
Curr Breast Cancer Rep
|
2011
|
0.79
|
|
80
|
Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.
|
Neuro Oncol
|
2007
|
0.79
|
|
81
|
Challenges in clinical studies with multiple imaging probes.
|
Nucl Med Biol
|
2007
|
0.79
|
|
82
|
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
|
Clin Cancer Res
|
2006
|
0.79
|
|
83
|
ACR appropriateness criteria palpable breast masses.
|
J Am Coll Radiol
|
2013
|
0.78
|
|
84
|
Evaluating the impact of new imaging tests: promises and pitfalls.
|
J Natl Cancer Inst
|
2012
|
0.78
|
|
85
|
Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results.
|
Mol Imaging
|
2002
|
0.78
|
|
86
|
Positron emission tomography imaging as a cancer biomarker.
|
Expert Rev Mol Diagn
|
2007
|
0.77
|
|
87
|
Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.
|
PET Clin
|
2009
|
0.77
|
|
88
|
[¹⁸F]fluorodeoxyglucose positron emission tomography-computed tomography in breast cancer: when... and when not?
|
J Clin Oncol
|
2012
|
0.75
|
|
89
|
A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy.
|
Phys Med Biol
|
2017
|
0.75
|
|
90
|
ABNM position statement: Nuclear medicine professional competency and scope of practice.
|
J Nucl Med
|
2011
|
0.75
|
|
91
|
ABNM celebrates 40th anniversary.
|
J Nucl Med
|
2011
|
0.75
|
|
92
|
131I therapy using rhTSH stimulation and dosimetry in metastatic malignant struma ovarii.
|
Clin Nucl Med
|
2014
|
0.75
|
|
93
|
ACR Appropriateness Criteria® stage I breast carcinoma.
|
J Am Coll Radiol
|
2012
|
0.75
|
|
94
|
Radiotracer breast cancer imaging: Beyond FDG and MIBI.
|
Phys Med
|
2006
|
0.75
|
|
95
|
Precise Localization of Occult Gastrointestinal Hemorrhage Using Dynamic SPECT/CT.
|
Clin Nucl Med
|
2016
|
0.75
|